Methods and means for determining treatment of subjects with exogenous somatotropin  

N.G.E. Smits (Inventor), M.H. Blokland (Inventor), M.W.F. Nielen (Inventor)

Research output: PatentOther research output

Abstract

Described are methods for determining whether a subject has been treated with exogenous somatotropin. The disclosure further relates to kits for determining whether a subject has been treated with exogenous somatotropin, and to the use of such kits for determining whether a subject has been treated with exogenous somatotropin.
Original languageEnglish
Patent numberUS2017354717
Priority date9/06/16
Publication statusPublished - 14 Dec 2017

Fingerprint

Growth Hormone
Disclosure

Cite this

@misc{53474205d54b453db0f0b0f53b165010,
title = "Methods and means for determining treatment of subjects with exogenous somatotropin  ",
abstract = "Described are methods for determining whether a subject has been treated with exogenous somatotropin. The disclosure further relates to kits for determining whether a subject has been treated with exogenous somatotropin, and to the use of such kits for determining whether a subject has been treated with exogenous somatotropin.",
author = "N.G.E. Smits and M.H. Blokland and M.W.F. Nielen",
year = "2017",
month = "12",
day = "14",
language = "English",
type = "Patent",
note = "US2017354717",

}

TY - PAT

T1 - Methods and means for determining treatment of subjects with exogenous somatotropin  

AU - Smits, N.G.E.

AU - Blokland, M.H.

AU - Nielen, M.W.F.

PY - 2017/12/14

Y1 - 2017/12/14

N2 - Described are methods for determining whether a subject has been treated with exogenous somatotropin. The disclosure further relates to kits for determining whether a subject has been treated with exogenous somatotropin, and to the use of such kits for determining whether a subject has been treated with exogenous somatotropin.

AB - Described are methods for determining whether a subject has been treated with exogenous somatotropin. The disclosure further relates to kits for determining whether a subject has been treated with exogenous somatotropin, and to the use of such kits for determining whether a subject has been treated with exogenous somatotropin.

M3 - Patent

M1 - US2017354717

ER -